1-5 of 5
Sandra Kluth
Close
Sort by
Journal Articles

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

Clinical Trials & Observations
Carmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, Janine Altmüller, Holger Thiele, Jasmin Bahlo, Sandra Kluth, Giuliano Crispatzu, Marco Herling, Joanna Schiller, Anja Engelke, Eugen Tausch, Hartmut Döhner, Kirsten Fischer, Valentin Goede, Peter Nürnberg, Hans Christian Reinhardt, Stephan Stilgenbauer, Michael Hallek, Karl-Anton Kreuzer
Journal: Blood
Blood (2016) 128 (3): 395–404.
https://doi.org/10.1182/blood-2016-01-691550
Published: 2016
Includes: Supplemental data
Journal Articles

Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Dan A. Landau, MD PhD, Eugen Tausch, MD, Sebastian Böttcher, MD PD, Chip Stewart, PhD, Ivana Bozic, Iganty Leischner, Daniel Rosebrock, Amaro Taylor-Weiner, BS, Daniel Mertens, PhD, Carrie Sougnez, Sabrina Kless, Michael Kneba, Matthias Ritgen, Sandra Kluth, Jasmin Bahlo, Anna-Maria Fink, MD, Kirsten Fischer, MD, Stacey Gabriel, Eric Lander, PhD, Hartmut Dohner, MD, Michael Hallek, MD, Donna S Neuberg, ScD, Martin Nowak, Gad Getz, PhD, Stephan Stilgenbauer, Catherine J. Wu, MD
Journal: Blood
Blood (2015) 126 (23): 362.
https://doi.org/10.1182/blood.V126.23.362.362
Published: 2015
Journal Articles

Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Gabor Kovacs, MD, Jasmin Bahlo, Sandra Kluth, Paula Cramer, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Carolin Gross-Ophoff-Mueller, MD, Petra Langerbeins, MD, Christian Maurer, MD, Julia von Tresckow, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Valentin Goede, MD
Journal: Blood
Blood (2015) 126 (23): 4156.
https://doi.org/10.1182/blood.V126.23.4156.4156
Published: 2015
Journal Articles

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Dan A. Landau, MD PhD, Eugen Tausch, MD, Amaro N Taylor-Weiner, BS, Sebastian Bottcher, MD, Jasmin Bahlo, Chip Stewart, PhD, Jennifer Edelmann, MD, Sandra Kluth, Dr., Daniel Mertens, PhD, Michael Kneba, MD PhD, Sabrina Kless, Carrie Sougnez, Kirsten Fischer, MD, Matthias Ritgen, Stacey Gabriel, PhD, Eric Lander, PhD, Hartmut Dohner, MD, Michael Hallek, MD, Gad Getz, PhD, Donna Neuberg, ScD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD
Journal: Blood
Blood (2014) 124 (21): 1938.
https://doi.org/10.1182/blood.V124.21.1938.1938
Published: 2014
Journal Articles

Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)

Gabor Kovacs, MD, Sebastian Boettcher, MD, Jasmin Bahlo, Sandra Kluth, Dr., Matthias Ritgen, Anna Maria Fink, MD, Irene Stodden, Paula Cramer, MD, Julia von Tresckow, MD, Christian Maurer, MD, Hartmut Doehner, Prof., Stephan Stilgenbauer, MD, Michael Kneba, MD PhD, Kirsten Fischer, Michael Hallek, MD, Barbara Eichhorst, MD
Journal: Blood
Blood (2014) 124 (21): 23.
https://doi.org/10.1182/blood.V124.21.23.23
Published: 2014